Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and/or anti PD-1/L1.

Trial Details

NCT ID

NCT06472713

Phase

PHASE2

Sponsor

Ming-Yuan Chen

Status

RECRUITING

Cancer Type

Nasopharyngeal Head and Neck Cancer

Interventions

Mitoxantrone hydrochloride liposome injection
PD-1 Inhibitors

Locations (sample)

Zhuhai, Guangdong, China|22.27694,113.56778

Key Eligibility Criteria

Willing to participate in the study, sign the informed consent form (ICF), and comply with study plan visits, treatment plans, laboratory tests, an…
Nasopharyngeal carcinoma confirmed by histopathology (differentiated or undifferentiated non-keratinous carcinoma).
Age ≥ 18 \& ≤ 70 years.
PS (Performance Status) score 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →